WallStSmart
DGX

Quest Diagnostics Incorporated

NYSE: DGX · HEALTHCARE · DIAGNOSTICS & RESEARCH

$189.32
-2.94% today

Updated 2026-04-29

Market cap
$20.96B
P/E ratio
20.92
P/S ratio
1.86x
EPS (TTM)
$9.05
Dividend yield
1.67%
52W range
$162 – $213
Volume
0.9M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Quest Diagnostics Incorporated (DGX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$189.32
Consensus
$208.62
+10.19%
2030 Target
$1,504.95
+694.92%
DCF
$165.53
-26.45% MoS
13 analysts:
5 Buy8 Hold0 Sell

Management guidance

Quest Diagnostics provided FY2026 guidance above analyst estimates on February 10, 2026, forecasting revenue growth and profit expansion. The company guides for 2026 revenue of approximately $11.87B (7.5% growth) based on strong lab test demand momentum, chronic care disease management initiatives, and advanced diagnostics expansion. Management emphasized accelerating growth drivers including AI-powered diagnostic tools and expanded consumer testing services.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$2,514.85
$14.0B Rev × 20x P/S
Base case (2030)
$1,504.95
$14.0B Rev × 12x P/S
Bear case (2030)
$1,009.90
$14.0B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$9.3B$9.9B$11.0B$11.9B$12.3B$12.8B$13.4B$14.0B
Revenue growth—6.7%11.8%7.5%3.7%4.4%4.4%4.5%
EPS$8.71$8.92$9.85$10.74$11.55$12.15$12.75$13.40
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$1,287.13$1,326.73$1,386.14$1,445.55$1,504.95

Catalysts & risks

Growth catalysts
+ AI companion tool for patient lab result interpretation driving patient engagement and repeat testing
+ Chronic care disease management expansion as key growth driver with reimbursement tailwinds
+ Advanced diagnostics portfolio growth including novel flow cytometry MRD blood test for myeloma
+ Dividend increase (7.5% to $0.86/share) and $1B share repurchase authorization signal management confidence
+ Q1 2026 earnings (April 21) likely to demonstrate sustained momentum from Q4 beat
+ Strategic board addition of Timothy Wentworth (former Walgreens/Express Scripts CEO) suggests M&A or operational expansion plans
Key risks
- Medicare reimbursement rate cuts could compress margins despite volume growth
- Rising operational costs (labor, technology infrastructure) pressuring profit margins
- Competitive intensity from Labcorp (LH) and specialized diagnostics players in high-growth segments
- Economic slowdown reducing discretionary consumer testing demand
- Regulatory scrutiny on diagnostics reimbursement and pricing transparency
- Integration execution risk if pursuing M&A strategy signaled by new Chief Strategy & M&A Officer appointment

Methodology

Quest Diagnostics Incorporated's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 13 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.